Literature DB >> 11282192

Increment of recombinant hepatitis B surface antigen-specific T-cell precursors after revaccination of slow responder children.

M A Avanzini1, C Belloni, R Soncini, L Ciardelli, A de Silvestri, A Pistorio, C Tinelli, R Maccario, G Rondini.   

Abstract

The aim of the study was to investigate the in vitro T-cell response to recombinant hepatitis B (rHBsAg) in a group of children (defined as "slow responders") vaccinated at birth, presenting antibody levels < 10 mIU/ml after the vaccination schedule, and developing anti-rHBs antibodies after revaccination. T-cell mediated immune response towards rHBsAg was evaluated in 35 healthy children in "bulk" culture experiments (19 responders and 16 slow responders) and by limiting dilution analysis (nine responders and five slow responders) to quantify the frequency of proliferating T lymphocyte-precursors (PTL-p). Before the booster dose, lymphocytes from slow responder children failed to proliferate to rHBsAg, while a normal proliferation was observed in all responders. A statistically significant difference in rHBsAg-specific PTLp frequencies was observed between the two groups. Among the slow responder group, a significant increase of PTLp was observed after the supplementary vaccine dose.Nevertheless, PTLp frequencies remained significantly lower than those measured in responders. These results suggest a role for follow-up of slow responder children over time, in order to perform booster vaccination when inadequate anti-HBs titre is present.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282192     DOI: 10.1016/s0264-410x(01)00007-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  T and B cell responses to HDM allergens and antigens.

Authors:  Wayne R Thomas; Belinda J Hales
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 2.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  House dust allergy and immunotherapy.

Authors:  Wayne R Thomas
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

4.  Microphysiologic Human Tissue Constructs Reproduce Autologous Age-Specific BCG and HBV Primary Immunization in vitro.

Authors:  Guzman Sanchez-Schmitz; Chad R Stevens; Ian A Bettencourt; Peter J Flynn; Klaus Schmitz-Abe; Gil Metser; David Hamm; Kristoffer J Jensen; Christine Benn; Ofer Levy
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

5.  Immune responses to inhalant allergens.

Authors:  Wayne R Thomas; Belinda J Hales
Journal:  World Allergy Organ J       Date:  2008-06       Impact factor: 4.084

Review 6.  Immune response to vaccines in children with celiac disease.

Authors:  Caterina Anania; Francesca Olivero; Alessandra Spagnolo; Claudio Chiesa; Lucia Pacifico
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

7.  Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24highCD38high Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders.

Authors:  Nina Körber; Laureen Pohl; Birgit Weinberger; Beatrix Grubeck-Loebenstein; Andrea Wawer; Percy A Knolle; Hedwig Roggendorf; Ulrike Protzer; Tanja Bauer
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.